ASH data to watch: GlycoMimetics, Ambit, Emergent

Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition became public on 7 November, and GlycoMimetics postponed its initial public offering on 8 November, but all three companies have data worth watching when ASH welcomes doctors and scientists to New Orleans from 7 to 10 December.

Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition became public on 7 November, and GlycoMimetics postponed its initial public offering on 8 November, but all three companies have data worth watching when ASH welcomes doctors and scientists to New Orleans from 7 to 10 December.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.